Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (14)	4/29/2004 10:58:05 AM
From: tuck	Read Replies (1) of 107

>>9:42AM Barrier Therapeutics IPO prices in middle of range (BTRX) 15.00: Barrier Therapeutics prices its IPO at $15, in the middle of the expected $14-$16 range. This biotech company is focused in the field of dermatology. It has eight product candidates in various stages of clinical development. The four most advanced are in or entering Phase III clinical trials. The co believes there is a significant commercial opportunity for a co focused specifically on the treatment of dermatological diseases, given the fragmented nature of the dermatology market and the clinical limitations of currently approved treatments.... The biotech IPO trains keeps rolling this year. This is the first one since CORT on April 14, which has already fallen below its $12 offering price... BTRX priced fairly well relative to other recent biotech IPOs. We're noticing that the IPOs with Tier One lead underwriters tend to price better. This is a 5 mln share deal, led by Morgan Stanley and will begin trading today.<< Courtesy of Briefing.com. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next